Further work from our group demonstrated that apoA-I mimetics like 4F and 6F work primarily in the gut to inhibit gut inflammation and M/M activation [11–14], and oral apoA-I mimetics demonstrate therapeutic efficacy in several inflammatory diseases in animal models including cancer, cardiovascular and inflammatory bowel disease [11–14]. Here, APOA1 is linked to cancer.